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Induction of cell cycle-dependent cytotoxicity and apoptosis by
new heterodinucleoside phosphate dimers of
5-fluorodeoxyuridine in PC-3 human prostate cancer cells
Abstract
Fluorodeoxyuridine (5-FdUrd) is an antineoplastic agent with clinical activity against different types of
solid tumours. To enhance the effectiveness of this drug, we have synthesised new heterodinucleoside
phosphate dimers of 5-FdUrd. These dimers were compared to 5-FdUrd for their cytotoxic effect and the
cell cycle dependence of cytotoxicity, as well as for their capacity to induce apoptosis and inhibit
thymidylate synthetase (TS) in androgen-independent human PC-3 prostate tumour cells. Incubation of
the cells with the dimers N(4)-palmitoyl-2'-deoxycytidylyl-(3'-->5')-5-fluoro-2'-deoxyuri din e
(dCpam-5-FdUrd) and 2'-deoxy-5-flourouridylyl-(3'-->5')-2'-deoxy-5-fluoro-N(4)-octa decylc ytidine
(5-FdUrd-5-FdC18) resulted in a marked cytotoxicity with IC(50) values of 4 microM, similar to
5-FdUrd. In contrast to 5-FdUrd, 100% toxicity was achieved with concentrations of 100-200 microM
5-FdUrd-5-FdC18. Flow cytometric analysis revealed an increase in the cell population in S-phase after
treatment with 5-FdUrd, 5-FdUrd-5-FdC18, and dCpam-5-FdUrd from 36 to 63%, 50%, and 77%,
respectively. dCpam-5-FdUrd was more potent than 5-FdUrd in arresting the cell cycle. Significant
S-phase arrest was indicated by a decreased proportion of cells in G1- and G2/M-phases. Cell cycle
arrest and inhibition of cell proliferation were followed by apoptosis, as shown by a 6- to 8-fold
increased binding of Apo2.7 antibody, a 9- to 11-fold increase in caspase-3 activity, DNA
fragmentation, and by cell morphology showing the appearance of apoptotic bodies. Importantly,
5-FdUrd-5-FdC18 increased the number of apoptotic cells to 160% compared to 5-FdUrd under the
same conditions. As with 5-FdUrd, the two dimers also inhibited TS in a time- and
concentration-dependent manner, although requiring 100-fold higher concentrations. In conclusion,
dCpam-5-FdUrd and 5-FdUrd-5-FdC18 exert stronger cytotoxicity and induce more S-phase arrest and
apoptosis than does 5-FdUrd in PC-3 cells, suggesting their potential role in the treatment of human
prostate cancer.
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ABSTRACT. Fluorodeoxyuridine (5-FdUrd) is an antineoplastic agent with clinical activity against different
types of solid tumours. To enhance the effectiveness of this drug, we have synthesised new heterodinucleoside
phosphate dimers of 5-FdUrd. These dimers were compared to 5-FdUrd for their cytotoxic effect and the cell
cycle dependence of cytotoxicity, as well as for their capacity to induce apoptosis and inhibit thymidylate
synthetase (TS) in androgen-independent human PC-3 prostate tumour cells. Incubation of the cells with the
dimers N4-palmitoyl-29-deoxycytidylyl-(39359)-5-fluoro-29-deoxyuridine (dCpam-5-FdUrd) and 29-deoxy-5-
flourouridylyl-(39359)-29-deoxy-5-fluoro-N4-octadecylcytidine (5-FdUrd-5-FdC18) resulted in a marked cyto-
toxicity with IC50 values of 4 mM, similar to 5-FdUrd. In contrast to 5-FdUrd, 100% toxicity was achieved with
concentrations of 100–200 mM 5-FdUrd-5-FdC18. Flow cytometric analysis revealed an increase in the cell
population in S-phase after treatment with 5-FdUrd, 5-FdUrd-5-FdC18, and dCpam-5-FdUrd from 36 to 63%,
50%, and 77%, respectively. dCpam-5-FdUrd was more potent than 5-FdUrd in arresting the cell cycle.
Significant S-phase arrest was indicated by a decreased proportion of cells in G1- and G2/M-phases. Cell cycle
arrest and inhibition of cell proliferation were followed by apoptosis, as shown by a 6- to 8-fold increased binding
of Apo2.7 antibody, a 9- to 11-fold increase in caspase-3 activity, DNA fragmentation, and by cell morphology
showing the appearance of apoptotic bodies. Importantly, 5-FdUrd-5-FdC18 increased the number of apoptotic
cells to 160% compared to 5-FdUrd under the same conditions. As with 5-FdUrd, the two dimers also inhibited
TS in a time- and concentration-dependent manner, although requiring 100-fold higher concentrations. In
conclusion, dCpam-5-FdUrd and 5-FdUrd-5-FdC18 exert stronger cytotoxicity and induce more S-phase arrest
and apoptosis than does 5-FdUrd in PC-3 cells, suggesting their potential role in the treatment of human prostate
cancer. BIOCHEM PHARMACOL 60;12:1887–1896, 2000. © 2000 Elsevier Science Inc.
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Prostate cancer incidence has been increasing in most
developed countries. In the United States, it has become
the most common cancer and is second only to lung cancer
as cause of cancer deaths [1]. Most cancers are diagnosed
when they are locally advanced or metastatic. The andro-
gen-dependent cancer cells initiate an apoptotic cascade in
human prostate cancer upon androgen ablation. However,
the androgen-independent cells continue to proliferate [2]
and are typically refractory to cytotoxic drugs. PC-3 is a
commonly used cell line in human prostate research which
is androgen-unresponsive and, as a result of a mutated gene,
null of p53 protein. This cell line is used as representative
of hormone-refractory human prostate cancer.
5-FU,\ resembling the pyrimidine bases uracil and thy-
mine, was specifically synthesised for clinical use. Cur-
rently, colon, breast, and ovarian cancers are treated with
this drug. After rapid transporter-mediated cell uptake, the
effect of 5-FU depends on the ability of tumour cells to form
the active nucleoside 5-FdUrd, the nucleotides 5-FdUMP
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and 5-FUMP, and the corresponding triphosphates
5-FdUTP and 5-FUTP. The triphosphates compete with
their normal counterparts for incorporation into RNA and
DNA, but the chemotherapeutic effect of 5-FdUrd is
primarily due to the inhibition of TS by 5-FdUMP. This
enzyme catalyses the reductive methylation of dUMP to
dTMP. For DNA replication and repair, this reaction
constitutes the sole intracellular de novo source of thymi-
dylate [3]. Predominantly rapidly proliferating cells require
TS, thereby representing an important target for cancer
chemotherapy [4].
To enhance the cytotoxic activity of 5-FdUrd, we have
developed a new strategy for masking nucleoside phos-
phates by the synthesis of amphiphilic dinucleoside phos-
phates [5]. These dimers contain 5-FdUMP, which is the
primary metabolite in the phosphorylation chain of
5-FdUrd. The amphiphilic/lipophilic nature provides the
dimers with new pharmacokinetic properties. We expect
that after cellular uptake the 59-monophosphate is released
by enzymatic cleavage. Consequently, low activities of
nucleoside-59-monophosphate kinases could be circum-
vented by these dimers, resulting in increased antitumour
activities.
In the present study, we examined two dimers of 5-FdUrd
for their effect on cell survival, their cell cycle dependence
on cytotoxicity, and for their capacity to induce apoptosis
in PC-3 cells. Furthermore, we analysed the ability of these
compounds to inhibit TS and therefore reduce or affect
DNA synthesis through the depletion of thymidine. Our
findings suggest that these novel dimers may be potential
therapeutic agents for the treatment of hormone-refractory
prostate tumours.
MATERIALS AND METHODS
Materials
BSA, BrdUrd, PI, Triton X-100, acid-washed activated
charcoal, dUMP, DAPI, the anti-a-tubulin, and the goat
anti-mouse immunoglobulin IgG-Cy3 antibodies were pur-
chased from Fluka. Phalloidin-Oregon Green and SYBR
Green II were from Molecular Probes. RPMI-1640 medium,
FBS, penicillin–streptomycin, L-glutamine, Hanks’ bal-
anced salt solution, and agar gel 2% were from Life
Technologies. Trypsin–EDTA was obtained from Bio-
chrom KG. RNAse A (EC 3.1.27.5), proteinase K (EC
3.4.21.14), and the 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1,2 benzene disulphonate (WST-1) assay
kit were from Boehringer Mannheim, Tween from Merck,
and T-70 dextran from Pharmacia. Digitonin and Mowiol
were purchased from Calbiochem. The monoclonal
Apo2.7-PE antibody was from IL Instrumentation Labora-
tory AG. The FITC-labelled anti-BrdUrd antibody and the
Ac-DEVD-AMC fluorogenic substrate were from Becton
Dickinson.
The heteronucleoside dimers dCpam-5-FdUrd and
5-FdUrd-5-FdC18 (Fig. 1) were synthesised according to
the methods described previously [5]. Briefly, the dimers
were obtained according to the phosphotriester method,
starting from 5-FdUrd. In comparison to highly hydrophilic
dinucleoside phosphate compounds which have octanol/
water partition coefficients (log P) around 0.01, the dimers
are amphiphilic/lipophilic with coefficients ranging from
0.1 to 5, which demonstrates their high affinity for lipid
membranes. Accordingly, the dimers can easily be incorpo-
rated at active concentrations into liposome membranes.
5-FdUrd was obtained from Hoffman La-Roche. In this
study, the drugs were dissolved in 0.9% NaCl.
Cell Culture
The human epithelial prostate tumour cell line PC-3 was
obtained from the German Collection of Microorganisms
and Cell Cultures, DSMZ. The cells were grown in RPMI-
1640 medium supplemented with 10% heat-inactivated
FBS, 100 U/mL of penicillin, 100 mg/mL of streptomycin,
and 2 mM L-glutamine in a humidified 5% CO2 atmosphere
at 37°.
Cytotoxicity Assay
Cell proliferation was evaluated by using the WST-1 cell
proliferation assay kit. Exponentially growing cells were
seeded in sterile 96-well plates and incubated for 24 hr.
Drugs were added to a final concentration of 12–200 mM.
Ninety-six hours later, the supernatant was removed and
100 mL of freshly diluted WST solution was added. The
plates were incubated for 30–60 min at 37° in a humidified
5% CO2 atmosphere. Cell viability was evaluated by
measurement of the absorption at 450 nm using a Dynatech
MR5000 plate reader (Microtec). IC50 values were calcu-
lated from interpolations of the graphical data.
Cell Cycle Analysis
Cells were seeded in 100-mm culture dishes and incubated
for 48 hr. Cells were exposed to various concentrations
(0–200 mM) of dimers and 5-FdUrd for 24 hr at 37° (5%
CO2) or for various time periods (0–48 hr) with 50 mM of
the drugs. After the specified period, the cells were incu-
bated with 10 mM BrdUrd for 30 min at 37° (5% CO2).
The supernatant with dead cells and the harvested living
cells were fixed in precooled (220°) ethanol (80%) and
stored at 220° for up to 3 days. BrdUrd/PI staining was
carried out as described previously [6]. Briefly, after centrif-
ugation, the cells were treated with 2 M HCl for 30 min at
20° and re-suspended in 50 mL PBS 1 0.5% Tween 20 1
1% BSA and incubated with FITC-labelled anti-BrdUrd
antibody for 30 min at 20° followed by addition of 1 mL
PBS 1 PI (10 mg/mL). Stained cells were analysed with an
Epics Elite Analyzer (Coulter). Single fluorescent samples
(FITC or PI) were used to optimise instrument settings and
ensure proper electronic compensation.
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Quantification of Apoptosis
Cells were treated as described for the cell cycle analysis.
After the incubation period, the supernatant with dead
cells and the harvested living cells were pooled and per-
meabilised by incubation on ice for 20 min with 100 mg/mL
of digitonin in PBS supplied with 2.5% FBS (v/v) and
0.01% NaN3. After permeabilisation, the cells were la-
belled with Apo2.7-PE for 15 min at room temperature in
the dark. For flow cytometric analysis, cells were re-
suspended in PBS supplied with 2.5% FBS (v/v) and 0.01%
NaN3 and stored on ice in the dark until analysis.
PARP Cleavage
Cells were treated as described for cell cycle analysis. After
incubation with the drugs, dead cells in supernatant and the
harvested living cells were counted and lysed with 10 mM
Tris, pH 7.5, 1130 mM NaCl, 11% Triton X-100, 110
mM NaH2PO4, 110 mM Na4P2O7, After centrifugation (5
min, 1400 g), 100 mL of the cell lysate was reacted with 20
mM PARP (Ac-DEVD-AMC) fluorogenic substrate in 20
mM HEPES, pH 7.5, 110% glycerol, 12 mM dithiothre-
itol for 2 hr at 37°. Released AMC from Ac-DEVD-AMC
was measured using a spectrofluorometer (Kontron SFM
23/23 LC) with excitation and emission wavelengths of 380
and 440 nm, respectively.
DNA Fragmentation
Cells were exposed for various time periods (0–96 hr) to 50
mM 5-FdUrd, dCpam-5-FdUrd, and 5-FdUrd-5-FdC18 at
37° (5% CO2). Colcemide (5 mg/mL) was used as a positive
control. DNA extraction was performed as described before
[6]. For detection, SYBR Green II dyed gels were scanned at
488 nm on a FlourImager 595 (Molecular Dynamics) using
an SYBR Green filter (530DF30).
FIG. 1. Chemical structures of the heterodinucleoside phosphate dimers. (A) N4-palmitoyl-2*-deoxycytidylyl-(3*35*)-5-fluoro-2*-
deoxyuridine (dCpam-5-FdUrd) and (B) 2*-deoxy-5-fluorouridylyl-(3*35*)-2*-deoxy-5-fluoro-N4-octadecylcytidine (5-FdUrd-5-
FdC18). The masked 5-fluoro-2*-deoxyuridine (5-FdUrd) is shown in the rectangle.
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Confocal and Electron Microscopy
Cells were incorporated in a 4:1 (v/v) mixture of rat tail
collagen (50,000 cells/100 mL) and RPMI 103 supple-
mented with 292 mM NaHCO3 and 75 mM NaOH. The
collagen–cell suspensions (20 mL) were seeded on Per-
manox chamber slides (Life Technologies). After solidifi-
cation of the collagen at 37°, the cells were incubated for 1
week in medium (5% CO2, 37°). Consecutively, they were
treated with 50 mM 5-FdUrd-5-FdC18 for 5 days. To
preserve the structural organisation of microtubules, cells
were washed in a microtubule protective buffer (MT buffer)
[7], permeabilised for 15 min with 1% Triton X-100 in MT
buffer, fixed for 30 min with 3% paraformaldehyde in MT
buffer at room temperature, followed by treatment with 0.1
M glycine in PBS at 4° for 15 min. The cells were stained
with anti-a-tubulin and goat anti-mouse immunoglobulin
IgG-Cy3 antibodies, with Phalloidin-Oregon Green, and
with DAPI. Cells were embedded in Mowiol and analysed
on a Zeiss LSM 410 inverted microscope. For electron
microscopy, PC-3 cells were seeded in 100-mm culture
dishes, incubated for 48 hr, and then exposed to 50 mM
5-FdUrd-5-FdC18 for 48 hr at 37° (5% CO2). Control cells
were not treated. The supernatant with dead cells and the
trypsinised living cells were pooled. Cells were fixed with
2.5% glutaraldehyde and embedded in Epon. Thin sections
were stained with 0.5% uranyl acetate and lead citrate.
After preparation, cells were examined on a Philips CM 10
electron microscope.
TS Assay
Activity of TS was measured by the release of tritium from
[5-3H]dUMP. Cells were seeded in 6-well plates and incu-
bated for 48 hr. After exposition to the drugs for 90 min at
different concentrations (0.01 nM to 100 mM) or for
various time periods (0–8 hr) with 0.1 mM at 37° (5%
CO2), the cells were treated with deoxyuridine-59-mono-
phosphate (10 mM) trace-labelled with 0.5 mCi/mL of
[5-3H]deoxyuridine-59-monophosphate (Amersham Phar-
macia Biotech) [8]. After incubation at 37° for 60 min, 0.2
mL medium was removed and added to 1 mL of a mixture
of ice-cold T-70 dextran and BSA-treated charcoal to
terminate the reaction. After 30 min at room temperature,
the probes were centrifuged (30 min, 4400 3 g) and the
radioactivity of the supernatant determined in a liquid
scintillation instrument (1900 TR Packard).
RESULTS
Cytotoxicity of dCpam-5-FdUrd and 5-FdUrd-5-FdC18
The cytotoxic effects of the dimers compared to 5-FdUrd in
PC-3 cells after a continuous 96-hr incubation are shown in
Fig. 2. IC50 values of the drugs are listed in the inset on Fig.
2, showing that dCpam-5-FdUrd and 5-FdUrd-5-FdC18
have IC50 values comparable to 5-FdUrd. However, in
contrast to 5-FdUrd, 100% toxicity was achieved at con-
centrations of 100 and 200 mM, respectively, after 96-hr
incubation with 5-FdUrd-5-FdC18. The time-dependent
FIG. 2. Cytotoxicity of the heterodinucleoside phosphates on PC-3 cells. Cells were treated for 96 hr at 12–200 mM. At 12 mM,
dCpam-5-FdUrd had 85–90% cytotoxicity compared to 5-FdUrd. In contrast, 5-FdUrd-5-FdC18 reached a cytotoxicity of 100% at a
concentration of 100 and 200 mM, respectively. Results are shown as means and SD of at least three independent experiments
performed in triplicate.
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cytotoxicity of the various drugs at 50 mM on PC-3 cells
showed that after a short incubation of 8 hr, 5-FdUrd was
more toxic than the dimers, resulting in survival fraction of
50.4 6 2.4%. At this time point, 5-FdUrd-5-FdC18 and
dCpam-5-FdUrd had a survival fraction of 67.3 6 6.8% and
79.4 6 3.6%. Both dimers reached 80% toxicity of 5-FdUrd
after 24 hr, which increased to 90% after 48-hr incubation
with the various drugs (data not shown). It is conceivable
that the dimers are more effective at higher concentrations
and longer incubation periods because of their prodrug
nature, resulting in persisting intracellular drug concentra-
tions over longer time periods as compared to 5-FdUrd.
After 24-hr incubation, the cytotoxic effects of 200 mM
5-FdUrd or dCpam-5-FdUrd were not significantly different
from those with 50 mM, whereas toxicity of 92.8 6 5.2%
was obtained with 200 mM 5-FdUrd-5-FdC18 (data not
shown).
Induction of Cell Cycle Arrest with dCpam-5-FdUrd
and 5-FdUrd-5-FdC18
Since the new anticancer dimers were found to inhibit cell
growth, it was of interest to determine whether the dimers
would interfere with cell cycle progression. The cell cycle
was analysed by flow cytometry (Fig. 3A), showing the
marked cell cycle arrest in the early S-phase caused by
treatment with dCpam-5-FdUrd (50 mM, 24 hr). The
individual changes in phase distribution after 24-hr incu-
bation with the various drugs at a concentration of 50 mM
are summarised in Fig. 3B. The dimers dCpam-5-FdUrd,
5-FdUrd-5-FdC18, and 5-FdUrd caused a marked reduction
in G1- and G2/M-phase cells and an increase in S-phase
cells after 24-hr incubation. The increase in S-phase cells
represents a stop in early S-phase, which we designated as
S0 (Fig. 3B, values in brackets). S0-phase cells belong to the
early S-phase based on their DNA content. They incorpo-
FIG. 3. The heterodinucleoside phosphate dimers cause alteration in cell cycle distribution of PC-3 cells. (A) Cell cycle distribution
of untreated cells (left panel) and cells treated with 50 mM dCpam-5-FdUrd for 24 hr (right panel) showing a marked cell cycle arrest
in the early S-phase (S0). Data are shown as contour plots with DNA content on the x-axis (PI staining) and BrdUrd content on the
y-axis (BrdUrd–FITC antibody). G1-, S-, and G2/M-phase distribution was quantified by gating the cell populations. (B) Cell cycle
distribution after 24-hr incubation with 50 mM drugs. Like 5-FdUrd, dCpam-5-FdUrd and 5-FdUrd-5-FdC18 caused an increase in
S-phase cells (total S-phase cell fraction in percent). The increase in S-phase cells always correlated with an increase in early S-phase
(S0; percent in brackets). Data are means of at least two independent experiments performed in duplicate.
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rate BrdUrd into DNA without DNA elongation, probably
due to strand breaks. 5-FdUrd-5-FdC18 had strong effect,
arresting cells in the S-phase (S-arrested). A linear increase
in these cells, which do not incorporate BrdUrd, from 0.3 6
0.1 to 6.1 6 1.0% after 48 hr was observed. In comparison
with 5-FdUrd and dCpam-5-FdUrd, this cell population
increased by more than 200% (data not shown).
Induction of Apoptosis of dCpam-5-FdUrd and 5-FdUrd-
5-FdC18
Quantification of apoptotic cells was carried out with the
Apo2.7 monoclonal antibody that reacts preferentially with
cells undergoing apoptosis [9]. The various effects on
induction of apoptosis by the drugs are summarised in Fig.
4. Characteristic staining of apoptotic cells with the
Apo2.7 antibody for untreated cells and cells treated with
50 mM 5-FdUrd-5-FdC18 are shown in Fig. 4A. After 48-
or 96-hr incubation time, 1.2 6 0.2% and 6.1 6 2.8%,
respectively, of untreated cells (control) were apoptotic,
whereas drug treatment increased the apoptotic cell frac-
tion to 3–7% after 48 hr and to 20–55% after 96 hr (Fig.
4B). 5-FdUrd-5-FdC18 was nearly twice as effective as
5-FdUrd, inducing 55% apoptotic cells in comparison to
only 34% induced by 5-FdUrd. Apoptosis was confirmed by
agarose gel electrophoresis as shown in Fig. 4C, demon-
strating the characteristic DNA ladders after drug treat-
ment. Colcemide-treated cells were included as a positive
control for DNA fragmentation.
To determine whether the derivatives lead to the acti-
vation of caspase proteases, we studied the proteolytic
cleavage of the caspase substrate PARP, which is involved
in DNA repair. The drugs induce a time-dependent PARP
cleavage in PC-3 cells. Treatment for 24 to 96 hr with
5-FdUrd and 5-FdUrd-5-FdC18 resulted in a linear
caspase-3 activation, whereas induction with dCpam-dC-
pam-5-FdUrd was delayed by 24 hr. After 48 hr, the
caspase-3 activity was 2- to 4-fold increased and after 72 hr
5 to 8 times. The highest cleavage activity was seen after 96
hr of incubation, resulting in a 9- to 11-fold increase in
caspase-3 activity in comparison to the untreated control
(data not shown).
Changes in Cellular and Nuclear Morphology
To examine the structure of the microtubules, actin fila-
ments, and the nuclei, we compared untreated control cells
(Fig. 5, A, C, and E) with 5-FdUrd-5-FdC18-treated cells
(Fig. 5, B, D, and F) by confocal laser scanning microscopy.
In contrast to untreated cells, drug-treated tumour cells
embedded in collagen did not proliferate. Compared with
the controls, where cells had a well-developed cytoskeleton
of actin, PC-S cells treated for 120 hr with 50 mM
5-FdUrd-5-FdC18 had completely disrupted actin filaments
(Fig. 5, C and D), as visualised by Phalloidin-Oregon Green
staining. The microtubules remained unaltered. Fluores-
cence microscopy of cells stained with the DNA fluoro-
chrome DAPI revealed the presence of apoptotic nuclei
with condensed and fragmented DNA in PC-3 cells treated
with 5-FdUrd-5-FdC18 (Fig. 5F). Apoptotic nuclei were
observed only sporadically in control cells (Fig. 5E).
The morphological changes in PC-3 cells after a 48-hr
exposure to 5-FdUrd-5-FdC18 at 50 mM were also assessed
by electron microscopy (Fig. 5, G and H). About 10% of
the analysed cells displayed the characteristic formation of
FIG. 4. Incubation with heterodinucleoside phosphate dimers induced apoptosis in PC-3 cells. (A) Flow cytometric detection of
Apo2.7-PE staining in untreated cells (control) and in cells treated for 96 hr with 50 mM 5-FdUrd-5-FdC18. Apoptotic cell death was
quantified by gating the Apo2.7-PE-positive cell population. (B) Apoptotic cell fraction after 48- and 96-hr drug treatment at 50 mM.
(C) DNA fragmentation: 123-pb marker, lane 1; 5-FdUrd, lane 2; dCpam-5-FdUrd, lane 3; 5-FdUrd-5-FdC18, lane 4. Colcemide
(lane 5) was used as positive control for apoptosis. Untreated cells (lane 6) did not shown DNA fragmentation. Results are shown as
means and SD of two separate experiments performed in duplicate.
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apoptotic bodies, containing condensed chromatin and
intact organelles such as mitochondria and endoplasmatic
reticulum. In the depicted cell in Fig. 5H, the cytoplasm
was almost completely fractionated into vesicles. Control
cells (Fig. 5G) did not display abnormal chromatin con-
densation or apoptotic bodies. Less than five percent of the
control cells had disrupted membranes and organelles, the
characteristic features of late apoptosis or necrosis.
TS Inhibition by dCpam-5-FdUrd and 5-FdUrd-5-
FdC18
The chemotherapeutic effect of 5-FdUrd is primarily due to
the inhibition of TS by 5-FdUMP. Measurement of TS
activity in PC-3 cells in situ indicated that all tested
compounds inhibited TS activity in a time- as well as in a
dose-dependent manner (Fig. 6). dCpam-5-FdUrd and
5-FdUrd-5-FdC18 were effective as inhibitors of TS activ-
ity, and a nearly complete inhibition was reached after
90-min incubation with 1 mM of the dimers (Fig. 6A).
5-FdUrd had the same effect at the 100-fold lower concen-
tration of 0.01 mM (Fig. 6A). Moreover, in the time-
dependent experiments with drug concentrations of 0.1
mM, 5-FdUrd reacted rapidly, reaching 95% inhibition of
TS activity already after 30 min (Fig. 6B), whereas dCpam-
5-FdUrd reached 50% inhibition only after 3 hr and
5-FdUrd-5-FdC18 after 5 hr. The delayed inhibition of TS
with the dimers again suggests that 5-FdUrd has to be
released from the dimers to exert an inhibitory action on
the thymidylate synthetase.
DISCUSSION
Increased proliferation and decreased cell death (apoptosis)
are two major processes that contribute to the progression
of tumour cell growth. Consequently, agents that can
inhibit cell proliferation or induce apoptosis are of great
therapeutic value in preventing tumour cell growth. In the
present study, we have evaluated and compared the effect of
two new agents on cell growth and apoptosis in hormone-
independent PC-3 cells. Our results show that compared to
the clinically used 5-FdUrd, these novel antitumour agents
exert stronger cytotoxicity due to a drastic cell cycle arrest
and apoptosis.
Specifically, 5-FU inhibits cell proliferation predomi-
nantly through thymidine depletion followed by S-phase
arrest. Accordingly, we observed that dimer-treated PC-3
cells were arrested in the early S-phase, whereas untreated
control cells showed no change in cell cycle distribution.
The effect of the dimers was seen after 8-hr incubation and
increased up to 48 hr as demonstrated by flow cytometry
analysis. The new amphiphilic heterodinucleoside phos-
phate dimers of 5-FdUrd strongly inhibited cell prolifera-
FIG. 5. Collagen-embedded PC-3 cells treated with 5-FdUrd-5-FdC18 (50 mM, 120 hr) showed apoptotic bodies in confocal
microscopy. The cells were triple-stained for F-actin (green; A–D), a-tubulin (red; A and B), and cell nuclei (blue; A, B, E, F).
Untreated cells are shown in panels A, C, and E and cells treated with 5-FdUrd-5-FdC18 in B, D, and F. Treated cells were reduced
in numbers and displayed morphological changes. After drug treatment, the structure of actin was completely disrupted (D) in
comparison to control cells (C). Nuclei of treated cells were fragmented into characteristic apoptotic bodies (F), whereas nuclei of
control cells remained dense and fragmentation was seen only rarely (E). All pictures represent single optical sections. G, electron
micrographs of an untreated PC-3 cell and (H) a cell treated with 50 mM of 5-FdUrd-5-FdC18 for 48 hr. The latter is fragmented into
vesicles with various densities, which contain morphologically unaltered organelles such as mitochondria and endoplasmatic reticulum.
Cytotoxic effects of Heterodinucleoside Dimers of 5-FdUrd 1893
tion in PC-3 cells in time- and dose-dependent manner. At
a low concentration of 12 mM, dCpam-FdUrd caused 90%
cytotoxicity compared to 5-FdUrd. Importantly, at higher
concentrations of 100 and 200 mM, the new dimers reached
a toxicity of 100% after 96-hr incubation. Consequently,
the new derivatives are also cytotoxic for the 10% of cells
which seem to be resistant to 5-FdUrd. It is conceivable
that high cytotoxic dimer concentrations are required in
the in vitro setting because the prodrugs have to be cleaved
by enzymes that may be present only at low concentrations.
However, it will be important to achieve these high
concentrations in vivo as well, without causing too strong
toxic side effects.
Recently, new compounds were found to be cytotoxic for
human prostate tumour cells. The nucleoside drug gemcit-
abine, which is a synthetic antimetabolite of the pyrimidine
nucleotide metabolism, inhibited cell growth and colony
formation of the androgen-sensitive prostate tumour cell
line LNCaP and the androgen-sensitive cells PC-3 and
DU-145 [10]. Colony formation could be suppressed,
whereas cell viability did not fall below 10%. The synthetic
retinoids fenretinide and CD437 induced S-phase arrest
FIG. 6. TS enzyme activity in PC-3 cells was inhibited by the heterodinucleoside phosphate dimers in (A) a dose-dependent manner
(90-min incubation time) and (B) a time-dependent manner (0.1-mM drug concentration). TS activity values are shown as percent of
untreated control. Data are means and SD of at least two independent experiments performed in duplicate.
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and apoptosis in human prostate tumour cells [11, 12].
While fenretinide completely inhibited PC-3 cell growth as
the dimers did, the synthetic retinoid CD437 did not reach
this cytotoxicity even after 6 days continuous incubation.
Apoptosis has emerged as a significant therapeutic target
for the effective elimination of cancer cells [13, 14]. In
agreement with others [12, 15], we have found that a
continuous drug exposure was required to induce apoptosis
in PC-3 cells. Studies with Apo2.7 antibody showed that
the drugs induced significant proportions of apoptotic cell
fractions after prolonged incubations of 96 hr. 5-FdUrd-5-
FdC18 was the most potent inducing agent at 50 mM,
resulting in a nearly twice as high apoptotic cell fraction as
5-FdUrd. Interestingly, 5-FdUrd, dCpam-5-FdUrd, and
5-FdUrd-5-FdC18 exhibited comparable toxicity in PC-3
cells after 48- and 96-hr incubation, but only 5-FdUrd-5-
FdC18 induced more than 50% of the cells to undergo
apoptosis after 96-hr continuous incubation. This finding
may be due to the fact that the other drugs induced more
non-apoptotic cell deaths. Significantly, our experiments
showed that exposure of the cells to the dimers resulted in
the activation of caspase-3, with cleavage of PARP and
subsequent internucleosomal degradation of genomic
DNA. For 5-FdUrd-5-FdC18, apoptosis was confirmed by
electron microscopy, where after 48-hr exposure we found
about 10% of all cells with condensed chromatin and
apoptotic bodies. 5-FdUrd-5-FdC18 also acts on the cy-
toskeleton, leading to disruption of actin filaments but
leaving the microtubule structure intact.
The delayed induction of apoptotic cell death can
possibly be explained by this cell line having low propensity
to undergo apoptosis. The p53 tumour suppressor gene has
been shown to be an essential component of the apoptotic
pathway induced by genotoxic insults [16]. Therefore, it
can be assumed that the absence of wild-type p53 in PC-3
cells was a contributing factor to the long induction times.
Experiments on lymphocytes of p53-deficient mice showed
that p53-null thymocytes were resistant to DNA damage-
induced apoptosis by etoposide and irradiation, but that
their response to glucocorticoids was unaltered by the
absence of p53 [17–19]. These data imply the existence of
p53-dependent and -independent pathways for the induc-
tion of apoptosis. In PC-3 cells, wild-type p53 does not
seem to be an effector of induced apoptosis. Rather, it
appears to be involved in setting the threshold for apoptosis
induction directly or by affecting the transcription of other
regulatory genes of apoptosis [14, 20]. A recent study
reported that cell death of PC-3 prostate tumour cells can
result from the inhibition of proteasome activity, which is
also independent of p53 and functional Bcl-2 [21].
Interestingly, dCpam-5-FdUrd and 5-FdUrd-5-FdC18
specifically repress TS, suggesting that the dimers act as
prodrugs that are cleaved intracellularly into the mono-
phosphorylated molecule 5-FdUMP, which in turn inhibits
TS. This also explains the longer incubation times and the
higher concentrations needed to inhibit TS activity to the
same extent as 5-FdUrd.
It is possible that 5-FdUrd-5-FdC18 is more potent than
the other two drugs because the molecule contains not only
the masked 5-FdUrd or its monophosphate (5-FdUMP) but
also an additional molecule with a potential cytotoxic
activity, namely the 5-FdC18 moiety of the dimer. With
the similar lipophilic molecule NOAC, we have detected
the hydrophilic metabolites arabinosyl cytosine (ara-C) and
arabinosyl uracil (ara-U) in mice, which were formed by
metabolic cleavage of the alkyl chain from the parent
molecule [22]. Thus, it might be possible that in 5-FdUrd-
5-FdC18 the alkyl chain can also be cleaved and, with an
additional oxidation reaction, 5-FdUrd and subsequently
5-FdUMP are formed. Further studies with the dimers are
needed to verify these assumptions in in vivo experiments.
The development of pharmacological agents that induce
cell death in p53-independent cells may prove useful in the
treatment of cancer patients, given the frequency of these
molecular alterations in human tumours and the associa-
tion of these alterations with therapy failure. Our results
suggest that the new dimers have a potential value as new
therapeutic agents against androgen-insensitive prostate
carcinoma through the inhibition of TS activity and
induction of a p53-independent apoptotic cascade.
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